Impact of Obesity and Metabolic Syndrome on IBD Outcomes.
Maya MahmoudWing-Kin SynPublished in: Digestive diseases and sciences (2024)
Contrary to visceral adiposity, obesity does not consistently result in an increased risk of IBD-related complications. Patients with IBD have a higher risk of acute arterial events, likely linked to systemic inflammation. Substantial evidence suggests that obesity has a negative impact on the response to IBD treatment, with this effect being most thoroughly studied in biologics and immunomodulators. The rates of overall complications and post-operative infections are higher in patients who are obese. There are limited but promising data regarding the impact of weight loss techniques, including exercise, medications, and bariatric interventions, on the outcomes in IBD. Both obesity and diabetes have adverse effects on the overall quality of life and place an increased financial burden on the IBD population. A growing body of evidence indicates a connection between obesity and associated metabolic comorbidities and negative outcomes in IBD, yet further efforts are required to fully understand this relationship.
Keyphrases
- weight loss
- metabolic syndrome
- insulin resistance
- bariatric surgery
- type diabetes
- roux en y gastric bypass
- glycemic control
- weight gain
- gastric bypass
- ulcerative colitis
- high fat diet induced
- adipose tissue
- end stage renal disease
- risk factors
- obese patients
- physical activity
- chronic kidney disease
- ejection fraction
- liver failure
- cardiovascular disease
- skeletal muscle
- uric acid
- healthcare
- prognostic factors
- deep learning
- body composition
- big data
- respiratory failure